Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2003 2
2010 2
2011 3
2013 1
2014 4
2015 1
2016 4
2017 3
2018 6
2019 4
2020 8
2021 3
2022 2
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR, Åvall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL, Lund B, Lindahl G, Hietanen S, Peen U, Dimoula M, Roed H, Ør Knudsen A, Staff S, Krog Vistisen A, Bjørge L, Mäenpää JU; AVANOVA investigators. Mirza MR, et al. Among authors: staff s. Lancet Oncol. 2019 Oct;20(10):1409-1419. doi: 10.1016/S1470-2045(19)30515-7. Epub 2019 Aug 29. Lancet Oncol. 2019. PMID: 31474354 Clinical Trial.
ROR1-STAT3 signaling contributes to ovarian cancer intra-tumor heterogeneity.
Piki E, Dini A, Raivola J, Salokas K, Zhang K, Varjosalo M, Pellinen T, Välimäki K, Veskimäe KT, Staff S, Hautaniemi S, Murumägi A, Ungureanu D. Piki E, et al. Among authors: staff s. Cell Death Discov. 2023 Jul 3;9(1):222. doi: 10.1038/s41420-023-01527-6. Cell Death Discov. 2023. PMID: 37400436 Free PMC article.
PErsonalized TReatment for Endometrial Carcinoma (PETREC): study design and methods of a prospective Finnish multicenter trial.
Loukovaara M, Bützow R, Staff S, Mäenpää M, Faltinová M, Lassus H, Veijalainen O, Grönvall M, Vaalavirta L, Kuikka E, Haataja M, Urpilainen E, Simojoki M, Anttila M, Auranen A. Loukovaara M, et al. Among authors: staff s. Int J Gynecol Cancer. 2023 Nov 6;33(11):1807-1811. doi: 10.1136/ijgc-2023-004939. Int J Gynecol Cancer. 2023. PMID: 37813479 Clinical Trial.
Sensitive circulating tumor DNA-based residual disease detection in epithelial ovarian cancer.
Kallio HM, Savolainen K, Virtanen T, Ryyppö L, Selin H, Martikainen P, Staff S, Kivinummi K, Sipola J, Vuorinen J, Nikkola J, Nykter M, Auranen A, Annala M. Kallio HM, et al. Among authors: staff s. Life Sci Alliance. 2024 Apr 5;7(6):e202402658. doi: 10.26508/lsa.202402658. Print 2024 Jun. Life Sci Alliance. 2024. PMID: 38580393 Free PMC article.
[Belted dialysis – ethically sound treatment or abuse?].
Aasebø W, Halvorsen CE, Staff S. Aasebø W, et al. Among authors: staff s. Tidsskr Nor Laegeforen. 2018 Jan 8;138(1). doi: 10.4045/tidsskr.17.0791. Print 2018 Jan 9. Tidsskr Nor Laegeforen. 2018. PMID: 29313623 Free article. Norwegian. No abstract available.
Cesarean scar defect: a prospective study on risk factors.
Antila-Långsjö RM, Mäenpää JU, Huhtala HS, Tomás EI, Staff SM. Antila-Långsjö RM, et al. Among authors: staff sm. Am J Obstet Gynecol. 2018 Nov;219(5):458.e1-458.e8. doi: 10.1016/j.ajog.2018.09.004. Epub 2018 Sep 18. Am J Obstet Gynecol. 2018. PMID: 30240650
48 results